NCT07020806View on ClinicalTrials.gov

[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Metastatic Lobular Breast Carcinoma
Interventions
DRUG

[68Ga]Ga DOTA-5G

Patients will be injected with up to 5 mCi of \[68Ga\]Ga DOTA-5G and imaged at 1 and 2 hours post injection.

Trial Locations (1)

95817

RECRUITING

University of California Davis, Sacramento

All Listed Sponsors
collaborator

Dr. Helen K Chew, University of California Davis

UNKNOWN

collaborator

Dr. Cameron Foster, University of California Davis

UNKNOWN

collaborator

Society of Nuclear Medicine and Molecular Imaging

UNKNOWN

lead

University of California, Davis

OTHER